Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308395 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
A Phase 3 study, sponsored by Sol-Gel Technologies.
- Terminated
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
NCT04308395 is a Phase 3 study that was terminated before completion, run by Sol-Gel Technologies. The registered enrollment target is 108 participants.
The verdict
NCT04308395, a Phase 3 study, was terminated before completion, sponsored by Sol-Gel Technologies.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
Interventions
- DRUG Patidegib Topical Gel, 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2021-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04308395
The ClinicalTrials.gov registry entry for NCT04308395 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patidegib Topical Gel, 2% is the first listed.
NCT04308395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04308395 about?
NCT04308395 is a clinical study titled "Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)". This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
What is the current status of trial NCT04308395?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2020-06-03. Estimated completion is 2021-07-14.
What interventions are being tested in trial NCT04308395?
The interventions under investigation include: Patidegib Topical Gel, 2% (DRUG).
Who is sponsoring clinical trial NCT04308395?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.